These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37678151)

  • 1. Cystic fibrosis liver disease in the post-modulator era.
    Narkewicz MR
    Curr Opin Pulm Med; 2023 Nov; 29(6):621-625. PubMed ID: 37678151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators.
    Wajda KE; Roesch EA; Gifford AH
    Curr Opin Pulm Med; 2023 Nov; 29(6):580-586. PubMed ID: 37611027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
    Tabori H; Schneider J; Lüth S; Zagoya C; Barucha A; Lehmann T; Kauf E; Barth A; Mainz JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Airway clearance after highly effective CFTR modulators: Normalizing life and reducing treatment burden.
    Goetz DM; Frederick CK; Perez G; Borowitz D
    Pediatr Pulmonol; 2023 Aug; 58(8):2375-2380. PubMed ID: 37232336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era.
    Wilschanski M; Peckham D
    Curr Opin Pulm Med; 2022 Nov; 28(6):577-583. PubMed ID: 36102602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
    Lahiri T; Sullivan JS
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Clinical Outcomes of Highly Effective Modulator Therapy.
    Gifford AH; Taylor-Cousar JL; Davies JC; McNally P
    Clin Chest Med; 2022 Dec; 43(4):677-695. PubMed ID: 36344074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nontuberculous Mycobacteria in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Regulator Modulators.
    Burke A; Thomson RM; Wainwright CE; Bell SC
    Semin Respir Crit Care Med; 2023 Apr; 44(2):287-296. PubMed ID: 36649736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators.
    Sathe M; Moshiree B; Aliaj E; Lee M; Hudson J; Gifford A; Attel S; Gamel B; Freedman SD; Schwarzenberg SJ; Freeman AJ
    Pediatr Pulmonol; 2023 Mar; 58(3):811-818. PubMed ID: 36448312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
    Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
    Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing Plain Radiograph with ultra-low dose CT thorax in cystic fibrosis (CF) in the era of CFTR modulation and its impact on cumulative effective dose.
    Sheahan KP; O'Mahony AT; Morrissy D; Ibrahim H; Crowley C; Waldron MG; Sokol-Randell D; McMahon A; Maher MM; O'Connor OJ; Plant BJ
    J Cyst Fibros; 2023 Jul; 22(4):715-721. PubMed ID: 37400300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.
    Vincken S; Verbanck S; Braun S; Buyck N; Knoop C; Vanderhelst E
    Acta Clin Belg; 2023 Aug; 78(4):280-284. PubMed ID: 36415912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of CFTR modulators 2020.
    Goetz DM; Savant AP
    Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
    Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
    J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.